Abstract
We retrospectively evaluated the efficacy of autologous hematopoietic stem cell transplantation (AHSCT) in 18 patients with rapidly progressive diffuse cutaneous systemic sclerosis (rp-dcSSc), and compared their disease outcomes with those of 36 demographically- and clinically-matched patients treated with conventional therapies. Cutaneous involvement, by performing modified Rodnan skin score (mRss), lung diffusion capacity, by measuring diffusing capacity of lung for carbon monoxide (DLCO), and disease activity, by applying the European Scleroderma Study Group (ESSG) scoring system, were the outcome variables measured at the baseline time and then every 12 months for the following 60 months in both the AHSCT-treated patients and the control group. In the AHSCT group, treatment-related mortality was 5.6%. In this group, both mRss and ESSG scores showed a significant reduction 1 year after AHSCT (P<0.002); and these results were maintained until the end of follow-up. Conversely, DLCO values remained stable during the whole period of follow-up. Survival rate of AHSCT group was much higher than that observed in the whole control group (P=0.0005). The probability that the ESSG score and mRss would remain at a high level, and DLCO could decrease, was significantly higher in the control group as a whole and in the subgroup of control patients treated with cyclophosphamide than in the AHSCT group. This study confirms that the AHSCT is effective in prolonging survival, as well as in inducing a rapid reduction of skin involvement and disease activity, and preserving lung function in patients with rp-dcSSc.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Gabrielli A, Avvedimento EV, Krieg T . Scleroderma. N Engl J Med 2009; 360: 1989–2003.
Nagaraja V, Denton CP, Khanna D . Old medications and new targeted therapies in systemic sclerosis. Rheumatology 2015; 54: 1944–1953.
Ferri C, Sebastiani M, Lo Monaco A, Iudici M, Giuggioli D, Furini F et al. Systemic sclerosis evolution of disease pathomorphosis and survival. Our experience on Italian patients' population and review of the literature. Autoimmun Rev 2014; 13: 1026–1034.
Kowal-Bielecka O, Landewé R, Avouac J, Chwiesko S, Miniati I, Czirjak L et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009; 68: 620–628.
Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE et al. Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655–2666.
Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006; 54: 3962–3970.
Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007; 176: 1026–1034.
Broad K, Pope JE . The efficacy of treatment for systemic sclerosis interstitial lung disease: results from a meta-analysis. Med Sci Monit 2010; 16: RA187–RA190.
Nannini C, West CP, Erwin PJ, Matteson EL . Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res Ther 2008; 10: R124.
Young A, Khanna D . Systemic sclerosis: a systematic review on therapeutic management from 2011 to 2014. Curr Opin Rheumatol 2015; 27: 241–248.
Naraghi K, van Laar JM . Update on stem cell transplantation for systemic sclerosis: recent trial results. Curr Rheumatol Rep 2013; 15: 326–331.
Burt RK, Shah SJ, Dill K, Grant T, Gheorghiade M, Schroeder J et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 2011; 378: 498–506.
van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 2014; 311: 2490–2498.
ClinicalTrials.gov:Scleroderma: Cyclophosphamide or Transplantation (SCOT). Available at http://www.clinicaltrials.gov/ct2/show/ NCT00114530?term=SCOT&rank=3. Accessed July 2015.
Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581–590.
van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 2013; 65: 2737–2747.
Clements PJ, Lachenbruch PA, Seibold JR, Zee B, Steen VD, Brennan P et al. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 1993; 20: 1892–1896.
Valentini G, Bencivelli W, Bombardieri S, D'Angelo S, Della Rossa A, Silman AJ et al. European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteria. Ann Rheum Dis 2003; 62: 901–903.
Medsger TA . Natural history of systemic sclerosis and the assessment of severity, functional state, and phychologic well-being. Rheum Dis Clin North Am 2003; 29: 255–273.
Oliveira MC, Labopin M, Henes J, Moore J, Papa ND, Cras et al. Does ex vivo CD34+ positive selection influence outcome after autologous hematopoietic stem cell transplantation in systemic sclerosis patients? Bone Marrow Transplant 2016; 51: 501–505.
Domsic RT, Rodriguez-Reyna T, Lucas M, Fertig N, Medsger TA Jr . Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma. Ann Rheum Dis 2011; 70: 104–109.
Maurer B, Graf N, Michel BA, Müller-Ladner U, Czirják L, Denton CP et al. Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database. Ann Rheum Dis 2015; 74: 1124–1131.
Burt RK, Oliveira MC, Shah SJ, Moraes DA, Simoes B, Gheorghiade M et al. Cardiac involvement and treatment-related mortality after non-myeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: a retrospective analysis. Lancet 2013; 381: 1116–1124.
van Laar JM, Naraghi K, Tyndall A . Haematopoietic stem cell transplantation for poor-prognosis systemic sclerosis. Rheumatology 2015; 54: 2126–2133.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Del Papa, N., Onida, F., Zaccara, E. et al. Autologous hematopoietic stem cell transplantation has better outcomes than conventional therapies in patients with rapidly progressive systemic sclerosis. Bone Marrow Transplant 52, 53–58 (2017). https://doi.org/10.1038/bmt.2016.211
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2016.211
This article is cited by
-
Learnings from clinical trials in patients with connective tissue disease-associated interstitial lung disease
Arthritis Research & Therapy (2023)
-
Management of Connective Tissue Disease–related Interstitial Lung Disease
Current Pulmonology Reports (2022)
-
Hematopoietic stem cell transplantation for systemic sclerosis: Brazilian experience
Advances in Rheumatology (2021)
-
French recommendations for the management of systemic sclerosis
Orphanet Journal of Rare Diseases (2021)
-
Systemische Sklerose – klinisches Bild, Diagnostik und Therapie
Der Hautarzt (2019)